Omega Therapeutics, Inc. (NASDAQ:OMGA) Stock Holdings Raised by Flagship Pioneering Inc.

Flagship Pioneering Inc. raised its holdings in Omega Therapeutics, Inc. (NASDAQ:OMGA) by 12.8% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 29,225,579 shares of the company’s stock after acquiring an additional 3,323,310 shares during the quarter. Omega Therapeutics makes up 6.8% of Flagship Pioneering Inc.’s holdings, making the stock its 2nd largest holding. Flagship Pioneering Inc. owned about 53.12% of Omega Therapeutics worth $176,230,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of OMGA. Tower Research Capital LLC TRC increased its holdings in Omega Therapeutics by 72.0% during the 3rd quarter. Tower Research Capital LLC TRC now owns 8,963 shares of the company’s stock worth $49,000 after purchasing an additional 3,753 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Omega Therapeutics during the first quarter valued at $25,000. California State Teachers Retirement System raised its holdings in shares of Omega Therapeutics by 137.2% in the first quarter. California State Teachers Retirement System now owns 9,475 shares of the company’s stock valued at $59,000 after acquiring an additional 5,480 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in Omega Therapeutics by 167.6% in the first quarter. Cubist Systematic Strategies LLC now owns 10,007 shares of the company’s stock worth $60,000 after acquiring an additional 6,267 shares during the period. Finally, Bank of America Corp DE lifted its stake in Omega Therapeutics by 72.0% in the first quarter. Bank of America Corp DE now owns 16,208 shares of the company’s stock worth $101,000 after acquiring an additional 6,787 shares during the period. Hedge funds and other institutional investors own 92.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on OMGA shares. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Omega Therapeutics in a report on Friday, September 1st. Chardan Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Omega Therapeutics in a research note on Friday, August 4th.

Omega Therapeutics Stock Down 1.0 %

OMGA traded down $0.03 on Tuesday, hitting $3.08. The company had a trading volume of 11,926 shares, compared to its average volume of 119,835. The stock has a market capitalization of $169.83 million, a price-to-earnings ratio of -1.40 and a beta of 0.74. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.71 and a current ratio of 3.71. The stock has a fifty day moving average price of $4.31 and a 200-day moving average price of $6.38. Omega Therapeutics, Inc. has a 12-month low of $3.04 and a 12-month high of $11.98.

Omega Therapeutics (NASDAQ:OMGA) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.63 million. Omega Therapeutics had a negative net margin of 4,283.72% and a negative return on equity of 97.34%. Analysts predict that Omega Therapeutics, Inc. will post -2.14 EPS for the current fiscal year.

Omega Therapeutics Profile

Omega Therapeutics, Inc operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.